Evidence map›Paper›PMID 35365899›Full record

ArticleEuropean journal of heart failure2022

Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank.

Tripti Rastogi, Frederick K Ho, Patrick Rossignol, Thomas Merkling, Javed Butler, Andrew Clark, Timothy Collier, Christian Delles, J Wouter Jukema, Stephane Heymans and 10 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 6 countries.

Tripti RastogiCentre d'Investigations Cliniques Plurithématique 1433, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, CHRU de Nancy, INSERM DCAC, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
Frederick K HoInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Patrick RossignolCentre d'Investigations Cliniques Plurithématique 1433, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, CHRU de Nancy, INSERM DCAC, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
Thomas MerklingCentre d'Investigations Cliniques Plurithématique 1433, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, CHRU de Nancy, INSERM DCAC, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
Javed ButlerDepartment of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
Andrew ClarkHull York Medical School, Castle Hill Hospital, Cottingham, UK.
Timothy CollierLondon School of Hygiene and Tropical Medicine, London, UK.
Christian DellesInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
J Wouter JukemaDepartment of Cardiology, Leiden University Medical Center, Leiden; Netherlands Heart Institute, Utrecht, The Netherlands.
Stephane HeymansDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Roberto LatiniIRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Alexandre MebazaaUniversité de Paris; APHP, University Hospitals Saint Louis Lariboisière, Inserm 942 MASCOT, Paris, France.
Pierpaolo PellicoriRobertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, UK.
Peter SeverInternational Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.
Jan A StaessenResearch Institute Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium.
Lutgarde ThijsResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium.
John G ClelandRobertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, UK.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Faiez ZannadCentre d'Investigations Cliniques Plurithématique 1433, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, CHRU de Nancy, INSERM DCAC, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
Nicolas GirerdCentre d'Investigations Cliniques Plurithématique 1433, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, CHRU de Nancy, INSERM DCAC, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
Inserm · FRUniversity of Glasgow · GBKU Leuven · BEHarefield Hospital · GBLeiden University Medical Center · NLLung Institute · USMaastricht University Medical Centre · NLMario Negri Institute for Pharmacological Research · ITThe Robertson Trust · GBUniversity of Hull · GBUniversity of London · GBUniversity of Mississippi · US

Funding

British Heart Foundation RE/18/6/34217Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

aimsMyocardial infarction (MI) is among the commonest attributable risk factors for heart failure (HF). We compared clinical characteristics associated with the progression to HF in patients with or without a history of MI in the HOMAGE cohort and validated our results in UK Biobank. METHODS AND

resultsDuring a follow-up of 5.2 (3.5-5.9) years, 177 (2.4%) patients with prior MI and 370 (1.92%) patients without prior MI experienced HF onset in the HOMAGE cohort (n = 26 478, history of MI: n = 7241). Older age, male sex and higher heart rate were significant risk factors of HF onset in patients with and without prior MI. Lower renal function was more strongly associated with HF onset in patients with prior MI. Higher body mass index (BMI), systolic blood pressure and blood glucose were significantly associated with HF onset only in patients without prior MI (all p for interactions <0.05). In the UK Biobank (n = 500 001, history of MI: n = 4555), higher BMI, glycated haemoglobin, diabetes and hypertension had a stronger association with HF onset in participants without prior MI compared to participants with MI (all p for interactions <0.05).

conclusionThe importance of clinical risk factors associated with HF onset is dependent on whether the patient has had a prior MI. Diabetes and hypertension are associated with new-onset HF only in the absence of MI history. Patients may benefit from targeted risk management based on MI history.

Indexed as

Diabetes MellitusHeart FailureHypertensionMyocardial InfarctionBiological Specimen BanksHumansMaleRisk FactorsUnited KingdomCardiovascular diseasesHeart failureMyocardial infarctionSurvival

Identifiers

PMID35365899
PMCPMC9542039
OpenAlexW4223531313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.